近日，由英国布里斯托大学孵化的AI生物科技初创公司CellVoyant宣布成功筹集760万英镑的种子资金。这笔资金将用于支持该公司使用人工智能成像技术，以帮助干细胞疗法开发商更有效地制造新疗法。
CellVoyant成立于布里斯托大学，专注于利用先进的人工智能技术来改善干细胞疗法的开发过程。该公司的技术能够提供更加精确的细胞成像，从而帮助研究人员更好地理解干细胞的行为和特性，这对于开发新的治疗方法至关重要。
本轮融资由Octopus Ventures领投，Horizons Ventures、Air Street Capital和Verve Ventures等知名投资机构参投。这些投资机构的加入不仅为CellVoyant带来了资金上的支持，也意味着他们对该公司的技术和商业模式的认可。
CellVoyant的创始人表示，这笔资金将用于进一步开发其人工智能成像技术，并扩大团队规模，以加速干细胞疗法的研发进程。随着全球对个性化医疗和再生医学的需求不断增长，CellVoyant的技术有望在医疗健康领域发挥重要作用。
英文标题：AI Biotech Startup CellVoyant Secures £7.6M Seed Funding
英文关键词：AI Biotech, Stem Cell Therapy, Seed Funding
英文新闻内容：
AI biotech startup CellVoyant, which spun out from the University of Bristol, has secured £7.6 million in seed funding. The investment will be used to support the company’s use of artificial intelligence imaging technology to aid stem cell therapy developers in creating new treatments more effectively.
Founded at the University of Bristol, CellVoyant specializes in leveraging advanced AI technology to enhance the development of stem cell therapies. The company’s technology offers more precise cell imaging, helping researchers better understand the behavior and characteristics of stem cells, which is crucial for developing new treatment methods.
The seed round was led by Octopus Ventures, with additional investment from Horizons Ventures, Air Street Capital, and Verve Ventures. The involvement of these investors not only brings financial support to CellVoyant but also signifies their recognition of the company’s technology and business model.
The founder of CellVoyant stated that the funding will be used to further develop its AI imaging technology and expand the team to accelerate the development of stem cell therapies. With the growing demand for personalized medicine and regenerative medicine worldwide, CellVoyant’s technology is poised to play a significant role in the healthcare sector.
【来源】https://sifted.eu/articles/ai-biotech-cellvoyant-raise
Views: 0